Search company, investor...
Search

Predict your next investment

Private Equity
accelmed.com

See what CB Insights has to offer

Investments

41

Portfolio Exits

8

Funds

4

About Accelmed

Accelmed is a private equity investment firm focused on long-term value creation for medical device companies. Accelmed invests in small and mid-cap private and public companies. Accelmed selectively invests in clinical stage Israeli companies that can benefit from Accelmed's insight, capital, and broad network. For non-Israeli companies, Accelmed, with access to hundreds of Israeli companies, offers a gateway to Israeli medical device products and innovations at attractive valuations.

Accelmed Headquarters Location

Azrieli, Triangle Building, 45th flr 132 Menachem Begin Road

Tel Aviv, 67023,

Israel

972-9-7885599

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Accelmed News

TearLab Closes Acquisition By Accelmed Partners

Jul 9, 2020

TearLab Closes Acquisition By Accelmed Partners Advancing Company's Plans to Build Comprehensive Dry Eye Care Platform Author: Jul 9, 2020 10:06 AM EDT ESCONDIDO, Calif., July 9, 2020 /PRNewswire/ --  TearLab Corporation (TearLab), a leader in diagnostics for dry eye disease (DED), today announced their acquisition by Accelmed Partners II (AP-II). As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery™ platform and seek out targeted acquisition opportunities that support a comprehensive portfolio to better meet DED market dynamics and patient care needs. "We are very excited to close this transaction with TearLab. Over the past years we spent many days listening to ophthalmologists and optometrists and learning their needs. We are investing in an exceptional team that is primed to execute directly against some of the most important and frequently mentioned unmet needs," commented Accelmed Partners' General Partner, Lior Shav. "Working together, Accelmed and TearLab management will combine unique skills and expertise to create a stronger company poised to succeed in the DED market." The global DED market is projected to grow from $4.42 billion in 2018 to $7.73 billion by the end of 2026. 1 An increasing number of dry eye clinical trials, new therapeutic options coupled with continued investment in research and development activities, provide strong tailwinds to support this tremendous market opportunity in the coming years. "Diagnosis and management of ocular surface disease, blepharitis, and DED is important, not only because of patient complications associated with these conditions but also our growing awareness of the relationship between DED and quality of vision," shared Francis S. Mah, MD, Director of Cornea Service at Scripps Clinic ( La Jolla, CA) and Chair of ASCRS Cornea Clinical Committee. "I am delighted TearLab is pursuing a comprehensive portfolio as both eyecare professionals and patients alike will benefit from a greater understanding of this disease." DED is the most common chronic ophthalmic disorder. TearLab's years of experience and research in DED strongly position the company to provide the eyecare community with meaningful advances in this under-resourced and under-served market. "This is a promising new chapter for TearLab. Our investment into a wider portfolio of DED diagnostics and treatments will not only offer physicians a broader range of DED management strategies, but also strengthen our leadership position as experts in the dry eye space," stated Seph Jensen, TearLab's Chief Executive Officer. "The past few months have been extremely difficult for many practices as they recover from the impact of COVID-19. We aim to provide more opportunities for eye care practices to grow their services while enhancing care to patients." About TearLab CorporationTearLab Corporation ( www.tearlab.com ) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively testing for disease bio-markers in tears at the point-of-care. The TearLab ® Osmolarity Test, to aid in the diagnosis Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. About Accelmed Partners           Accelmed Partners ( www.accelmed.com ) is a leading U.S. based private equity firm focused on investments in commercial stage HealthTech companies. Accelmed is based in New York City. Fortune Business Insights, March 09, 2020 View original content: http://www.prnewswire.com/news-releases/tearlab-closes-acquisition-by-accelmed-partners-301090970.html

Accelmed Investments

41 Investments

Accelmed has made 41 investments. Their latest investment was in MedMinder Systems as part of their Private Equity on August 8, 2022.

CBI Logo

Accelmed Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/26/2022

Private Equity

MedMinder Systems

$10M

No

3

5/19/2022

Private Equity

Veranex

Yes

3

10/22/2021

Series B

Click Therapeutics

$52M

Yes

15

9/1/2021

Private Equity - III

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/26/2022

5/19/2022

10/22/2021

9/1/2021

6/7/2021

Round

Private Equity

Private Equity

Series B

Private Equity - III

Series B

Company

MedMinder Systems

Veranex

Click Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$10M

$52M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

3

15

10

10

Accelmed Portfolio Exits

8 Portfolio Exits

Accelmed has 8 portfolio exits. Their latest portfolio exit was CartiHeal on August 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/30/2021

Acquired

$99M

4

4/22/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

3/11/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

8/18/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/30/2021

4/22/2021

10/3/2019

3/11/2019

8/18/2016

Exit

Acquired

IPO

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Accelmed Acquisitions

3 Acquisitions

Accelmed acquired 3 companies. Their latest acquisition was Paltop Advanced Dental Solutions on August 04, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/4/2020

$99M

Acq - Fin

1

5/11/2020

Subscribe to see more

$99M

Subscribe to see more

10

6/4/2018

Private Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/4/2020

5/11/2020

6/4/2018

Investment Stage

Private Equity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Accelmed Fund History

4 Fund Histories

Accelmed has 4 funds, including Accelmed Partners II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/17/2021

Accelmed Partners II

$400M

3

3/9/2017

Accelmed Growth Partners

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2011

Accelmed Ventures I

Subscribe to see more

Subscribe to see more

$99M

10

Accelmed Ventures II

Subscribe to see more

Subscribe to see more

10

Closing Date

3/17/2021

3/9/2017

12/31/2011

Fund

Accelmed Partners II

Accelmed Growth Partners

Accelmed Ventures I

Accelmed Ventures II

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$400M

$99M

$99M

Sources

3

10

10

10

Accelmed Team

6 Team Members

Accelmed has 6 team members, including current Chief Technology Officer, Ilan Ben-Oren.

Name

Work History

Title

Status

Ilan Ben-Oren

Chief Technology Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Ilan Ben-Oren

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Technology Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.